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Abstract
Cardiac resynchronization therapy (CRT) is an important advance for the treatment of end-
-stage heart failure (HF). About 15–50% of HF is complicated by atrial fibrillation (AF),
associated with worsened outcomes. The presence of AF may interfere with optimal delivery of
CRT due to competition with biventricular (BiV) capture by conducted beats. Pacing algo-
rithms in newer devices may not ensure consistent CRT delivery during periods of rapid
ventricular rates. Atrioventricular junction ablation with permanent pacing eliminates interfe-
rence by conducted beats and provides complete BiV capture and is associated with improved
outcomes. Catheter ablation of AF is another promising alternative to maintain sinus rhythm in
patients with AF and HF. However, the optimal indications for CRT delivery for patients in this
complex cohort remain to be assessed in randomized clinical trials. (Cardiol J 2009; 16: 4–10)
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Introduction
Atrial fibrillation (AF) frequently coexists with
heart failure (HF); the two conditions may directly
predispose to each other. The prevalence of AF is
closely related to New York Heart Association
(NYHA) class. In approximate terms, the prevalen-
ce is 5% for NYHA functional class I, 10% to 25%
for class II to III, and as high as 50% for class IV
[1, 2]. The permanent form of AF [3] is present in
10% to 30% of patients with HF [4] and is associa-
ted with increased morbidity and mortality [5, 6].
The development of AF in the HF patient often
heralds a worse prognosis [6, 7]. For example, in the
Framingham study, the risk of death approximately
doubled in HF patients who experienced AF [7].
Cardiac resynchronization therapy (CRT) has
emerged as an important therapeutic modality for
patients with end-stage drug refractory HF [8, 9].
Currently, CRT therapy is employed to treat
patients who have ejection fraction (EF) £ 35%,
ventricular dyssynchrony (QRS duration ≥ 120 ms),
and NYHA class III to IV HF. Several clinical trials
have demonstrated the efficacy of CRT; however,
all major trials have included patients in sinus rhy-
thm [9–11].
Clinical trials of atrial fibrillation
and cardiac resynchronization therapy
Data for the efficacy of CRT in AF patients has
been obtained from observational studies and 1 ran-
domized trial that included AF patients. Leon et al.
[12] studied the effect of biventricular pacing (BiV)
on the functional status, quality of life, and hospita-
lization in patients with HF and AF. Twenty con-
secutive patients with severe HF (EF £ 35%,
NYHA class III /IV) prior atrioventricular junction
(AVJ) ablation and right ventricular (RV) pacing per-
formed for permanent AF of at least six months
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duration were studied. The investigators studied only
patients that underwent AVJ ablation, as it forced BiV
pacing to be delivered effectively without other inter-
ference. There was a significant improvement in
NYHA class and EF, a decrease in the number of ho-
spitalizations, and improved quality of life scores.
The MUSTIC (MUltisite STimulation in Car-
diomyopathies) trial was a randomized cross-over
study of 131 patients including 67 in sinus rhythm
and 64 in AF [13]. The trial demonstrated a similar
improvement in the 6-minute walk test in class III
HF patients following CRT, whether they were in
sinus rhythm or in AF. Of the 64 AF patients, only
37 patients completed both crossover phases, gre-
atly limiting the impact of the results. In addition,
all patients in AF had a slow ventricular rate trial
achieved through either spontaneous or induced
atrioventricular (AV) block; this criterion is impor-
tant because it probably distinguished a subset of
patients that were most likely to have a high de-
gree of BiV capture.
Molhoek et al. [14] evaluated the clinical re-
sponse and long-term survival of CRT in 60 patients
with NYHA class III/IV HF and decreased EF
(< 35%), of whom 30 were in sinus rhythm and
30 had chronic AF. The study showed that the im-
provement in clinical parameters (NYHA class,
exercise capacity, and quality of life score) was com-
parable between patients who had sinus rhythm and
those who had AF. In addition, 2-year survival rate
was similar in the 2 groups. Interestingly, 17 of the
30 AF patients had AVJ ablation.
Delnoy et al. [15] compared the efficacy of CRT
in 96 patients with chronic AF and 167 patients with
sinus rhythm. Echocardiographic and clinical para-
meters were evaluated at baseline and at 3 and
12 months. HF hospitalizations were compared the
year before and the year after CRT implantation.
Overall mortality and rates of hospitalization were
similar in both groups. However, among patients with
chronic AF, 22% had AVJ ablation and nearly 50% the
patients were in spontaneous or cardioverted sinus
rhythm. Among the AF patients, > 90% pacing was
achieved in > 90% of the patients at follow-up.
An underlying issue for all these studies is the
consistent and complete delivery of CRT. This is
important since the delivery of CRT is dependent
on effective and complete BiV capture. In patients
with AF, there is no AV synchrony, and thus an in-
ability to establish coordinated AV pacing; BiV cap-
ture is difficult to assure. Furthermore, patients
with AF often have intermittent or consistent ac-
celerated ventricular rates. Even when pacing
rates are well programmed, the high intrinsic ven-
tricular rates seen in some AF patients may inhibit
consistent pacing and capture [16]. Fusion and pseudo-
-fusion beats resulting from an interaction betwe-
en intrinsically conducted and paced beats may be
responsible for ineffective pacing, despite the ap-
parent delivery of CRT. This leads to inaccuracy and
overestimation of the effective pacing capture. Thus
it is imperative that in AF patients who undergo
CRT, close follow-up is necessary to ensure close
to 100% BiV capture [2].
Cardiac resynchronization therapy
pacing algorithms: Ventricular capture
Irregular heart rate is itself associated with
worsened cardiac function in patients with AF and
HF [17]. Ventricular rate control has been consi-
dered to be an important component of optimal CRT
delivery during rapid ventricular rates. Modern
CRT devices employ algorithms designed to maxi-
mize ventricular pacing during potentially disrup-
tive events such as rapidly conducted atrial arrhy-
thmias. Both Medtronic and Boston Scientific CRT
systems include algorithms that temporarily shor-
ten the post-ventricular atrial refractory period to
regain atrial tracking and restore resynchronization
after premature ventricular complexes or during
sinus tachycardia faster than the nominal upper rate
limit. For Medtronic devices, the Ventricular Sen-
se Response™ feature triggers pacing in one or both
ventricles after each RV-sensed event. Medtronic’s
Conducted AF Response™ resynchronizes conduc-
ted beats in AF up to a minimum R-R interval wi-
thout increasing ventricular rate. Boston Scienti-
fics Ventricular Rate Regularization™ algorithm is
intended to restore resynchronization and ventri-
cular regularity by pacing the ventricle during irre-
gular conduction of AF [18].
It is important to emphasize that the percen-
tage of BiV pacing alone, as recorded by the CRT
device, may be an ineffective surrogate of comple-
te and consistent BiV capture.  Fusion and pseudo-
-fusion beats resulting from an interaction betwe-
en intrinsically conducted and paced beats may be
responsible for ineffective pacing, despite the ap-
parent delivery of CRT as assessed by a high per-
centage of BiV pacing. We studied 18 patients with
permanent AF who underwent CRT [19]. All pa-
tients received medical therapy with digoxin, beta-
-blockers, and amiodarone for rate control, and de-
vice interrogation showed > 90% BiV pacing. At
a median of 12 months after device implant, the
patients were instructed to wear an ambulatory
12-lead Holter for 24 hours. Effective pacing was
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defined by the presence of more than 90% fully
paced beats with complete ventricular capture as
confirmed in all 12 leads. In all CRT devices, devi-
ce specific special pacing algorithms were activa-
ted. Despite advanced pacing algorithms and CRT
device counters showing > 90% pacing, in reality
only 44% of patients had effective pacing (> 90%
fully paced beats/24 h). The remaining 56% of pa-
tients met criteria for ineffective pacing; in these
patients, nearly 40% of pacing was accounted by fu-
sion and pseudo-fusion. Only patients with effective
pacing demonstrated response to CRT (≥ 1 NYHA
improvement) and had evidence of reverse remo-
delling. These results emphasize the importance of
effective BiV capture to ensure clinical response
from CRT, rather than using simple counts of pacing
delivery. It further underlies that, despite the CRT
counters showing a high degree of BiV pacing, com-
plete BiV capture may still be less than optimal.
Atrial pacing prevention algorithms
A vicious cycle exists between AF and HF; thus
interruption or prevention may be a worthwhile
therapeutic strategy. CRT combined with a refined
atrial tachyarrhythmia prevention pacing algorithm
appears to be an important addition in the manage-
ment of AF. The Atrial Dynamic Overdrive Pacing
Trial (ADOPT), designed to assess the clinical ef-
ficacy and safety of the AF suppression algorithm™
(St. Jude Medical) in patients with permanent pa-
cemaker with prior history of AF, demonstrated that
the overdrive atrial pacing algorithm was safe and
decreased the symptomatic AF burden [20]. Howe-
ver, all patients had normal EF and the primary
outcome was symptomatic AF burden. The Mana-
gement of Atrial fibrillation Suppression in AF-HF
COmorbidity Therapy (MASCOT) study evaluated
whether the addition of atrial overdrive pacing
(AOP) to CRT could reduce the incidence of per-
manent AF in patients with HF [21]. The study ran-
domized 394 patients with NYHA class III/IV HF
to either “AOP ON” or “AOP OFF”, following CRT
implantation. The overall incidence of permanent
AF was low and was similar for the two treatment
groups (n = 6 for “AOP OFF” and n = 7 for “AOP
ON”). It is likely that the advanced atrial remodel-
ling in the setting of HF and AF may preclude be-
nefit from atrial algorithms in this altered milieu.
Atrioventricular junction ablation
Destruction of AVJ and placement of a perma-
nent pacemaker has been used in patients with
AF with uncontrolled ventricular rates. However,
in patients with AF who undergo CRT therapy, AVJ
ablation is increasingly being viewed as an impor-
tant adjunct to ensure adequate CRT delivery. The
Post AV Nodal Ablation evaluation (PAVE) study
was a prospective, randomized trial comparing BiV
to RV pacing in patients with chronic atrial fibrilla-
tion undergoing AV node ablation [22]. The study
randomized 184 patients requiring AVJ to BiV (n =
= 103) or RV pacing system (n = 81). The study
endpoints were changes in the 6-minute walk test,
quality of life, and left ventricular ejection fraction.
At 6 months post-ablation, patients treated with BiV
pacing had significant improvement in 6-minute
walk distance in comparison to patients receiving
right ventricular pacing. There was a decrease in
EF in the RV paced group while EF remained sta-
ble in the BiV group.
Gasparini et al. [23] presented data on 673 con-
secutive patients (162 in AF, 511 in sinus rhythm).
Of the 162 AF patients, 114 patients underwent AVJ
ablation for inadequate BiV capture during follow-
-up, i.e. < 85% BiV capture. Patients in the sinus
rhythm and AF groups showed significant and su-
stained improvement in functional capacity, left
ventricular (LV) systolic function, and NYHA class.
However, within the AF group, only patients who
underwent ablation showed a significant increase of
EF, reverse remodelling, and improved exercise to-
lerance. No improvements were observed in AF pa-
tients who did not undergo ablation. The long-term
effect on mortality and hospitalization was subse-
quently assessed in the follow-up of 1285 consecu-
tive patients (1042 in sinus rhythm, 243 in AF) who
underwent CRT therapy [24]. In the AF group, an
arbitrary cut-off of more than 85% BiV pacing was
considered evidence of sufficient CRT delivery.
Patients with > 85% BiV pacing were continued on
rate control regimen while AVJ was performed if
£ 85% BiV pacing. At nearly 3 years of follow-up,
all-cause mortality and cardiac mortality was simi-
lar in the sinus rhythm group and the AF group. Wi-
thin the AF group, total mortality was significantly
better in the AVJ-ablation group compared to the
AF drug-treated group (Fig. 1, 2). Ferreira et al. [25]
also conducted a retrospective analysis of 131 con-
secutive HF patients who underwent CRT implan-
tation. The patients in 3 groups were considered:
sinus rhythm (n = 78), AF with AVJ ablation (n =
= 26), and AF without AVJ ablation (n = 27). The
primary outcomes were occurrence of cardiac de-
ath, hospitalization for HF, and improvement in
NYHA class. There was a significant improvement
in the NYHA class in all 3 groups. However, the
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proportion of responders was significantly lower in
AF patients without AVJ ablation (52 vs. 79% in
sinus rhythm and 85% in AF with AVJ ablation).
AF without AVJ ablation was independently associa-
ted with five-fold increase in mortality and six-fold
risk of hospitalization for HF during the first 12 mon-
ths. The outcomes of AF with AVJ ablation patients
were similar to the outcomes of patients in sinus
rhythm. The authors concluded that AF patients
display similar survival as sinus rhythm patients
provided that AVJ ablation is performed.
These data suggest that patients with AF and
HF may do better with the ‘ablate and pace’ strate-
gy. The AVJ ablation with placement of permanent
BiV pacemaker renders the patient pacemaker de-
pendent and ensures complete and consistent BiV
capture. CRT is delivered without fusion or pseu-
dofusion thus ensuring high quality BiV capture.
However, data from larger randomized clinical trials
will be needed before utilizing this as a standard prac-
tice since this would create a large number of pace-
maker-dependent HF patients. In addition, a small but
variable rate of spontaneous conversion of AF to
sinus rhythm has been reported after CRT [26, 27].
Catheter ablation of atrial fibrillation
In patients with permanent AF who undergo
CRT without AVJ ablation, a few studies have sug-
gested that cardioversion and aggressive rhythm
control result in better clinical outcomes [28, 29].
However, currently available antiarrhythmic drugs
(AAD) are only partially effective in maintaining
sinus rhythm, and this is achieved at the cost of
potential risk. In the Atrial Fibrillation Follow-Up
Investigation of Rhythm Management (AFFIRM)
Figure 1. Comparison of Kaplan-Meier estimates of overall (A), cardiac (B), and heart failure (C) survival between atrial
fibrillation (AF) patients who underwent atrioventricular junction ablation (AVJ-abl) and AF patients treated only with
negative chronotropic drugs (AF-drugs); the p values presented derive from the adjusted hazards ratio analysis
stratified according to the corresponding cause of death [24].
Figure 2. Hazard ratio estimates on the mode of death
were adjusted for centre, age, gender, aetiology, NYHA
class, QRS width, left ventricular ejection fraction and
device type. Hazard ratio estimates stratified according
to cause of death between atrial fibrillation (AF) pa-
tients who underwent atrioventricular junction ablation
(AVJ-abl) and patients treated with negative chronotro-
pic drugs (AF-drugs); hazard ratio estimates were adju-
sted for centre, age, gender, aetiology, NYHA class,
QRS width, left ventricular ejection fraction and device
type. Corresponding hazard ratio values for each cause
of death are indicated with a square, the bar represents
95% confidence interval range, and the p value for each
estimate is presented on the right of the figure [24].
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trial, the use of AAD was associated with an almost
50% increase in mortality, which offset the poten-
tial benefit of maintaining sinus rhythm [30]. Fur-
thermore, maintenance of sinus rhythm using AAD
in the setting of AF and HF does not improve su-
rvival or other important endpoints [31, 32]. In con-
trast, catheter ablation may offer another approach
for achieving sinus rhythm in these patients [32,
33]. Several clinical trials have demonstrated cathe-
ter ablation as a promising alternative (Table 1).
Chen et al. [34] studied 94 patients with decreased
EF (LVEF = 36%) who underwent catheter abla-
tion. The control group consisted of 283 patients
who had normal EF. At 14 months of follow-up the-
re was a 5% improvement in EF, and 73% of the
patients were free from AF recurrence in the de-
creased EF group. Hsu et al. [35] studied 58 con-
secutive patients with HF and LVEF < 45% who
underwent catheter ablation for AF and compared
their outcomes to a matched control group without
HF. Sinus rhythm was achieved in 78% of patients
with HF and in 84% of controls. In addition, patients
with HF had significant improvements in EF, LV
dimensions, exercise capacity, and quality of life
(Fig. 3). Tondo et al. [36] evaluated 40 patients with
LV dysfunction with EF < 40% and compared them
to 65 patients with normal ventricular function. Out-
comes included changes in LV function, maintenan-
ce of sinus rhythm, and quality of life during follow-up.
After a mean follow-up of 14 months, 87% of pa-
tients with impaired LV function and 92% of patients
with normal ventricular function were in sinus rhy-
thm, with or without antiarrhythmic therapy. A si-
gnificant improvement in LVEF was seen in pa-
tients with HF (33% to 47%). More recently, Choi
et al. [38] evaluated 15 patients with AF and symp-
tomatic LV dysfunction (EF £ 45%) referred for
ablation. These patients were compared to
a matched cohort treated medically for AF and LV
dysfunction. Baseline EF in the study group was
37%, and for the controls it was 34%. The groups
were similar in all respects. During the 16 months
after ablation, EF improved to 50% ± 13% along
with a significant improvement in NYHA class. In
the medically treated group, no improvement in EF
(36 ± 12%) or NYHA class was seen. Thus, compa-
red to pharmacologic therapy, ablation significantly
improved LV function and NYHA class in patients
with AF and symptomatic LV dysfunction. The re-
sults of these nonrandomized series provide a po-
tent rationale for a randomized clinical trial compa-
ring ablation to pharmacologic therapy.
Conclusions
Current evidence suggests that CRT is effec-
tive in patients with AF and HF. However, there
is no possibility of response to CRT if ventricular
capture does not occur during BiV pacing. In pa-
tients with HF and AF, there is no atrioventricular
Table 1. Clinical trials of catheter ablation in atrial fibrillation and left ventricular dysfunction.
Study Study population Results
Chen et al. [34] 94 patients with LVEF < 40% vs. 73% of patients with decreased EF and
Retrospective case 283 patients with normal EF 87% of patients with normal EF were free of AF
4.6% increase in LVEF, significant
improvement  in QoL
Hsu et al. [35] 58 consecutive patients with HF 78% of the patients with CHF and
Prospective study and LVEF < 45% vs. 84% of controls were free of AF
58 matched patients without HF Significant improvement in LVEF of 21 ± 13%,
exercise capacity, symptoms scores, and
QoL scores
Tondo et al. [36] 40 patients with LVEF < 40% vs. 87% of patients with decreased EF and
Prospective study 65 patients with normal ventricular 92% of patients with normal EF were free of AF
function Improvement in LVEF from 33% to 47%
Gentlesk et al. [37] Patients with reduced LVEF (£ 50%) 86% of patients in decreased LVEF and
Prospective study vs. patients with normal LVEF 87% of patients in normal EF were free of AF
LVEF increased from 42% to 56% after ablation
Choi et al. [38] 15 patients with AF and LVEF £ 45% Significant improvement in EF from
Retrospective referred for catheter ablation vs. 37% to 50%
case-control 15 matched patients treated with
analysis medical therapy
AF — atrial fibrillation; EF — ejection fraction; LVEF — left ventricular ejection fraction; QoL — quality of life; HF — heart failure; CHF — congestive
heart failure
series
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synchrony and BiV capture is difficult to assu-
re. The optimal method to ensure complete and
consistent BiV capture in patients with AF and
CRT remains to be determined. At this time, AVJ
ablation or AF ablation appear to be promising ad-
junctive modalities.
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